BioSpace News Archive

A mathematical model set up by an ad-hoc group of scientists indicates the number of currently infected novel coronavirus cases in China are on the decline as of February 12.

Bristol-Myers Squibb Company announced five-year follow-up results from the Phase 3 CheckMate -025 study, which continue to demonstrate that treatment with Opdivo delivers superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma compared to those treated with everolimus.

Informa Markets, the leading exhibition organiser in Malaysia, is supporting the government’s efforts to share factual and up-to-date information on the COVID-19 situation in Malaysia with the business community

Eisai presented results from a Phase 2 trial assessing the efficacy and safety of lenvatinib in combination with everolimus in patients with unresectable advanced or metastatic non-clear cell renal cell carcinoma at the 2020 Genitourinary Cancers Symposium in San Francisco from February 13-15.

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Adverum Biotechnologies, Inc. on behalf of investors..

Mirati Therapeutics, Inc. announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolumab in patients with advanced clear cell renal cell cancer who have documented progression on a prior VEGF-targeted therapy.

Further to my previous statements, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose a risk of significant harm to public health.

MDA, a Maxar Technologies company, announced that technology developed by its UK division in partnership with the UK Space Agency and the Canadian Space Agency has begun its journey to the International Space Station.

Updated results from CheckMate -214 study show that more than 50% of patients treated with Opdivo plus Yervoy were alive at 42 months compared to 39% of patients treated with sunitinib